Zhihong Zeng - Concepedia

Author

Zhihong Zeng

The University of Texas MD Anderson Cancer Center

Also Known As

Zeng Zhihong, Zhihong Zeng

Publications

875

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center

About

Zhihong Zeng is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, pharmacotherapy, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	125
2	Pathology	2	2	108
3	Health Sciences	1	1	56
4	Immunology	1	1	56
5	Molecular Medicine	1	1	56

Zhihong Zeng

Publications

858

Citations

H-Index

Page 1

	Year	Citations
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML Zhihong Zeng, Dos D. Sarbassov, Ismael Samudio, Blood	2006	342
Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies Karen Yee, Zhihong Zeng, Marina Konopleva, Clinical Cancer Research	2006	287
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Naval Daver, Yanis Boumber, Hagop M. Kantarjian, Clinical Cancer Research	2015	67
Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies. Curtis A. Lachowiez, Gautam Borthakur, Sanam Loghavi, Journal of Clinical Oncology ImmunologyPathologyPharmacotherapyMyeloid NeoplasiaBcl2 Inhibitor	2020	56
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias Brittany Knick Ragon, Hagop M. Kantarjian, Elias Jabbour, American Journal of Hematology Mixed-phenotype Acute LeukemiaPathologyPi3k InhibitorPharmacotherapyTumor Biology	2016	52
Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile Zhihong Zeng, Annelies Roobrouck, Geert Deschamps, Blood Advances	2024	19
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia Marlise R. Luskin, Shai Shimony, Julia Keating, Blood Advances	2024	18
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial Nicholas J. Short, Daniel Nguyen, Elias Jabbour, The Lancet Haematology Hematological MalignancyOncologyMixed-phenotype Acute LeukemiaSingle-centre Phase 2Hematology	2024	17

Page 1